Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Public ClinicalTrials.gov record NCT02475655. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to evaluate the safety and tolerability of ruxolitinib in HIV-positive adults who were virologically suppressed and who were on antiretroviral therapy (ART).
Study identification
- NCT ID
- NCT02475655
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 16, 2016 (Actual)
- Primary completion
- Feb 18, 2018 (Actual)
- Completion
- Apr 4, 2018 (Actual)
- Last update posted
- Nov 4, 2021
2016 – 2018
United States locations
- U.S. sites
- 14
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS | Birmingham | Alabama | 35294 | — |
| UCLA CARE Center CRS | Los Angeles | California | 90035 | — |
| UCSD Antiviral Research Center CRS | San Diego | California | 92103 | — |
| Ucsf Hiv/Aids Crs | San Francisco | California | 94110 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Washington University Therapeutics (WT) CRS | St Louis | Missouri | 63110-1010 | — |
| Weill Cornell Chelsea CRS | New York | New York | 10010 | — |
| Weill Cornell Uptown CRS | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS | Rochester | New York | 14642 | — |
| Cincinnati Clinical Research Site | Cincinnati | Ohio | 45219 | — |
| Case Clinical Research Site | Cleveland | Ohio | 44106 | — |
| Penn Therapeutics, CRS | Philadelphia | Pennsylvania | 19104 | — |
| The Miriam Hospital Clinical Research Site (TMH CRS) CRS | Providence | Rhode Island | 02906 | — |
| Vanderbilt Therapeutics (VT) CRS | Nashville | Tennessee | 37204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02475655, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 4, 2021 · Synced Oct 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02475655 live on ClinicalTrials.gov.